adplus-dvertising

New Imcivree Indication; Top Pediatric Endo Hospitals; Contrast Dye & Tots’ Thyroids

The FDA approved a new indication for setmelanotide (Imcivree), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome but rejected a new indication for Alström syndrome, Rhythm Pharmaceuticals announced.

The endocrine-disrupting chemicals PFOA and PFOS may be more harmful than previously thought, the Environmental Protection Agency warned. (AP)

According to a recent survey of U.S. adults, 79% said paying for insulin created a financial burden for them, even requiring taking on debt in some cases. (Forbes)

The Children’s Hospital of Philadelphia took the top spot on U.S. News & World Report‘s 2022-2023 top hospitals for pediatric diabetes & endocrinology. The #2 and #3 spots went to Boston Children’s Hospital and Cincinnati Children’s Hospital Medical Center, respectively.

After accidentally being exposed to his father’s testosterone gel, a 2-year-old boy began showing signs of puberty. (New York Post)

Pushing back on the FDA’s recent guidance recommending that children under 3 be monitored for hypothyroidism after exposure to intravascular iodine-containing contrast material, the American College of Radiology said there is “no convincing scientific evidence” at this time to support this kind of testing. (Journal of the American College of Radiology)

Compared with a traditional family-based behavioral treatment delivered in an academic center, a less intense guided self-help program delivered in the primary care setting was just as effective at reducing BMI in kids. (Pediatrics)

A 30-year Australian study found that greater fitness in childhood was linked with better cognition in midlife. (Journal of Science and Medicine in Sport)

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.